Literature DB >> 24368252

Exhaled nitric oxide and other exhaled biomarkers in bronchial challenge with exercise in asthmatic children: current knowledge.

Mario Barreto1, Rosanna Zambardi2, Maria Pia Villa2.   

Abstract

The fractional concentration of exhaled nitric oxide (FENO), a known marker of atopic-eosinophilic inflammation, may be used as a surrogate to assess exercise-induced bronchoconstriction (EIB) in asthmatic children. The predictive value of baseline FENO for EIB appears to be influenced by several factors, including age, atopy, current therapy with corticosteroids and measurement technique. Nonetheless, FENO cut-off values appear to be able to rule out EIB. FENO levels decrease during EIB, apparently through neural mechanisms rather than by decreased airway-epithelial surface. Partition of FENO into proximal and peripheral contributions of the respiratory tract may improve our understanding on NO exchange during exercise and help to screen subjects prone to EIB. Other biomarkers of inflammation and oxidative stress contained in exhaled gases and exhaled breath condensate (EBC) may shed light on the pathophysiology of EIB. Exhaled breath temperature is a promising real-time measurement whose routine use for assessing EIB warrants further investigation.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Asthma; Atopy; Biomarkers; Bronchoconstriction; Children.; Exercise challenge test; Exhaled nitric oxide

Mesh:

Substances:

Year:  2013        PMID: 24368252     DOI: 10.1016/j.prrv.2013.11.006

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN: 1526-0542            Impact factor:   2.726


  2 in total

Review 1.  Oxidative Stress and Bronchial Asthma in Children-Causes or Consequences?

Authors:  Milos Jesenak; Maria Zelieskova; Eva Babusikova
Journal:  Front Pediatr       Date:  2017-07-24       Impact factor: 3.418

2.  Serum BPI as a novel biomarker in asthma.

Authors:  Chen Xingyuan; Qiu Chen
Journal:  Allergy Asthma Clin Immunol       Date:  2020-06-18       Impact factor: 3.406

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.